Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antithrombotic therapy after cerebral ischemia]

P D Schellinger1, E Orberk, W Hacke

  • 1Neurologische Klinik, Ruprecht-Karls-Universität, Heidelberg.

Fortschritte Der Neurologie-Psychiatrie
|January 7, 1998
PubMed
Summary

Antithrombotic agents like ticlopidine and clopidogrel effectively reduce recurrent ischemic stroke risk. Combining dipyridamole with aspirin also shows benefits, but all treatments require balancing efficacy against bleeding risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Key design elements of successful acute ischemic stroke treatment trials.

Neurological research and practice·2023
Same author

Pulse pressure variability is associated with unfavorable outcomes in acute ischaemic stroke patients treated with intravenous thrombolysis.

European journal of neurology·2020
Same author

Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity.

European journal of neurology·2020
Same author

Histological stroke clot analysis after thrombectomy: Technical aspects and recommendations.

International journal of stroke : official journal of the International Stroke Society·2019
Same author

Angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical treatment: One-year interim results of SPACE-2.

International journal of stroke : official journal of the International Stroke Society·2019
Same author

[S2 guidelines on cryptogenic stroke and patent foramen ovale : Discordant interpretations].

Der Nervenarzt·2018

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Secondary stroke prevention is crucial after cerebral ischemia.
  • Antithrombotic agents are primary treatment options for preventing recurrent strokes.
  • Evaluating new antithrombotic therapies is essential for optimizing patient outcomes.

Purpose of the Study:

  • To review and discuss current antithrombotic treatment options for secondary prophylaxis of ischemic stroke.
  • To analyze the efficacy and safety profiles of various antithrombotic agents based on recent clinical trials.
  • To provide guidance on balancing therapeutic benefits against bleeding risks in stroke prevention.

Main Methods:

  • Review of multicenter studies including Ticlopidine Aspirin Stroke Study (TASS), Canadian American Ticlopidine Study (CATS), and Clopidogrel vs. Aspirin in Patients with Risk of Ischemic Events (CAPRIE).

Related Experiment Videos

  • Analysis of the 2nd European Stroke Prevention Study (ESPS 2) evaluating dipyridamole and aspirin combinations.
  • Evaluation of data from major trials on heparin and heparinoids, such as the Trial of Org 10172 in Acute Stroke Treatment (TOAST), International Stroke Trial (IST), and Chinese Acute Stroke Trial (CAST).

    • Main Results:

    • Ticlopidine demonstrated significant risk reduction for recurrent ischemic stroke compared to aspirin and placebo.
    • Clopidogrel showed comparable efficacy to ticlopidine but with a superior safety profile.
    • Combination therapy of dipyridamole and aspirin significantly reduced ischemic stroke risk compared to placebo.
    • Heparin and heparinoids showed diminishing roles in secondary stroke prevention due to increased bleeding rates and unproven benefits in major trials.

    Conclusions:

    • Ticlopidine and clopidogrel are effective antiplatelet agents for secondary stroke prevention.
    • Combination therapy with dipyridamole and aspirin offers a significant benefit in reducing stroke risk.
    • The use of antithrombotic agents necessitates careful consideration of the risk of bleeding versus therapeutic benefits, with regular reevaluation of treatment indications.